results

Lucas GC Limited Announces 1H 2025 Financial Results: Revenue at US$54.01 million with Increases in Gross Margin

October 31, 2025 17:00 ET  | Source: Lucas GC Limited NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Lucas GC…

1 month ago

AMSC to Report Second Quarter Fiscal Year 2025 Financial Results on November 5, 2025

October 31, 2025 16:33 ET  | Source: AMSC AYER, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- AMSC® (NASDAQ: AMSC), a…

1 month ago

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered…

1 month ago

Tenable Announces Third Quarter 2025 Financial Results

Tenable Exceeds Q3 Revenue and Profit Expectations, Raises Full-Year Outlook Revenue of $252.4 million, year-over-year growth of 11%Calculated current billings…

1 month ago

Climb Global Solutions Reports Third Quarter 2025 Results

EATONTOWN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Climb Global Solutions, Inc. (NASDAQ:CLMB) (“Climb” or the “Company”), a value-added global…

1 month ago

FormFactor, Inc. Reports 2025 Third Quarter Results

Q3 Revenue, Gross Margin and Earnings per Share Exceed the Midpoint of the Outlook Range; Expects to Deliver Higher Results in…

1 month ago

Jungbunzlauer Tricalcium Citrate Excipient Demonstrates Outstanding Results in Direct Compression Study

- New research confirms Jungbunzlauer's TCC TB supports efficient, high-quality tablet manufacturing across challenging pharmaceutical and nutraceutical applications - BASEL,…

1 month ago

Supermicro, Intel and Micron Collaborate on Record-Breaking Results for the STAC-M3 Quantitative Trading Benchmark

The STAC-M3 measures time-series database performance used in algorithmic trading and backtesting workloads Supermicro Petascale servers, Intel® Xeon® 6 processors,…

1 month ago

Varonis Announces Third Quarter 2025 Financial Results

Annual recurring revenues increased 18% year-over-yearSaaS ARR as a percentage of total ARR was approximately 76%Year-to-date cash from operations generated…

1 month ago

LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE

Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial…

1 month ago